Accueil   Diary - News   All news Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer

Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer

Radebeul, Germany & Lyon, France, September 15, 2017 -- RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental drug products, today announced the successful industrial GMP manufacturing, including packaging and quality control of RIBOXXIM®, a novel and highly potent Toll-like Receptor 3 (TLR3)-ligand.





Manufacturing has been performed with the patented process TENPORA® of RIBOXX in full compliance with the EU GMP requirements, and with the GMP specifications of the experimental drug.


RIBOXXIM® is a proprietary drug substance of RIBOXX PHARMACEUTICALS. It activates the innate immune system to eliminate cancer cells as a validated approach in immuno-oncology with the historical TLR3 ligand poly(I:C) and its derivatives.


RIBOXXIM® has been validated in multiple pre-clinical studies for immunotherapy of cancer. It displays unique physico-chemical and biological properties, as well as optimal biodisponibility with increased stability to degradation in body fluids such as human plasma. RIBOXXIM® is stable as a drug product in liquid form for several months.


Prof. Dr. Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS declared: "We are proud to have reached this important milestone in the development of TLR3 ligands, with a unique, highly potent and stable drug product as a better alternative to poly(I:C) and its derivatives. RIBOXXIM® is available for pharmaceuticals companies or universities developing clinical applications in immuno-oncology and therapeutic vaccines."


André Dupont, President of ACCINOV declared: “We are proud to be the manufacturer of this innovative experimental drug. This achievement demonstrates the high flexibility of the ACCINOV model.”

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree